The size of the European Liquid Biopsy Market is expected to increase at a CAGR of 21.45% in the forecast period and reach a value of USD 1233.15 million by 2025 from USD 466.69 million in 2020.
Europe Liquid Biopsy market led the global liquid biopsy market in 2019. In the coming years, the global liquid biopsy market is expected to undergo significant changes. Currently, the global market is just beginning, but it is still growing at a significant rate. Many startups and promising companies are entering the market.
Currently, in Europe Liquid Biopsy Market, research and development on cancer diagnosis focus on liquid biopsy. Market participants and research institutes are conducting extensive clinical trials to develop a sensitive liquid biopsy platform. In May 2018, Grail, a U.S.-based biotechnology company, raised $ 1 billion in venture capital and began early breast cancer research with 120,000 patients. In January 2018, researchers at Johns Hopkins University developed a test called CancerSEEK. The analysis includes more than 1,000 patients with nonmetastatic stage I to III ovary, stomach, liver, pancreas, esophagus, lung, colorectal, and breast cancer. Large-scale liquid biopsy studies aimed at facilitating early diagnosis of cancer may lead the market over the forecast period
Europe Liquid Biopsy Market, with the advantages of liquid biopsy over solid tissue biopsy, is presumed to show modest growth over the forecast period. In addition, the growing number of cancer patients and increasing awareness of minimally invasive cancer patients are supposed to drive market growth. The increase in pre-screening programs for cancer detection is presumed to provide market expansion opportunities.
The European liquid biopsy market is growing due to the high incidence of cancer and rising medical costs. The region is foreseen to multiply with respect to the development and use of liquid biopsy techniques.
The market players' increasing investment for growth and adoption of new technologies by hospital providers is expected to drive market growth in the region.
However, alternatives to liquid biopsy, uncertain reimbursement, and regulatory conditions are anticipated to hamper the regional market growth. High testing costs, a shortage of trained professionals, and fewer reimbursement policies can limit the growth of the European liquid biopsy market.
This Research Report segmented and sub-segmented the Europe Liquid Biopsy Market into the following categories:
Regionally, the Europe region is also showing high growth in liquid biopsy in the future. An increase in population, patients suffering from cancer, increasing awareness within the people, and the need to detect and recover cancer are some factors driving the market. Lung cancer is one of the most common diseases in European countries.
The number of cancer patient in the UK is increasing, where around 367,000 new cases are found every year. Most of the patient who dies is because of late detection, and liquid biopsy is used to detect and treat various types of cancer such as lung, breast, prostate and bowel. The government and non- government organizations are promoting the use of a liquid biopsy, which is likely to bolster the demand of the market. Growing expenditure on healthcare, especially in urban areas, is promoting the growth rate of the market. Many clinical trials are going on in the UK to develop an innovative treatment procedure for cancer.
Germany has the highest market in the Europe region, following the UK. There is a substantial rise in the number of a cancer patient in Germany. The government in Germany is collaborating with biotech companies to improve liquid biopsy techniques. Many institutes in Germany are researching liquid biopsy.
In France, the market share is to have a significant growth rate in the coming years. Government funding and growing prevalence to improve the healthcare services are fueling the demand of the market. There is a liquid biopsy online platform called Biobank Cote d’Azur. Launch of new products is also one of the factors for the market to grow.
Over 50% of total death in Spain is caused due to cancer. Thus liquid biopsy is used on a large scale to detect cancer at an early stage. There is a lab for the treatment of cancer in Spain. The liquid biopsy market is growing at a good rate in Italy.
Key market participants in the Europe Liquid Biopsy Market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences and HansaBiomed OU.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Cancer Type
5.1.1 Lung Cancer
5.1.2 Pancreatic Cancer
5.1.4 Other Visceral Cancers
5.2 By Sample Type
5.3 By Diagnostic Approach
5.3.1 Circulating Tumour cells (CTC)
5.3.2 Circulating Tumour DNA (ctDNA)
5.3.3 RNA in exosomes
5.3.4 Extra-Cellular Vesicles
5.4 By End Users
5.4.1 Reference Laboratories
5.4.2 Hospital/Physician Laboratories
5.4.3 Academic and Research Centers
5.4.4 Other End Users
6. Geographical Analysis
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Janssen Diagnostics
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.3 Rarecells SAS
8.4 Silicon Biosystems
8.5 SRI International
8.6 Myriad Genetics
8.8 Personal Genome Diagnostics
8.9 Sysmex Inostics
8.11 Exosome Diagnostics
8.12 HansaBiomed OU
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
a) List of Tables
b) List of Figures